Department of Cardiology, Angiology, Haemostaseology and Medical Intensive Care, Medical Faculty Mannheim, University Medical Centre Mannheim, Heidelberg University, Heidelberg, Germany.
European Center for AngioScience (ECAS), German Center for Cardiovascular Research (DZHK) Partner Site Heidelberg/Mannheim, Mannheim, Germany.
Ir J Med Sci. 2024 Feb;193(1):457-468. doi: 10.1007/s11845-023-03385-8. Epub 2023 May 19.
The study investigates the diagnostic and prognostic value of C-reactive protein (CRP) and procalcitonin (PCT) in patients with sepsis and septic shock.
Limited data regarding the prognostic value of CRP and PCT during the course of sepsis or septic shock is available.
Consecutive patients with sepsis and septic shock from 2019 to 2021 were included monocentrically. Blood samples were retrieved from the day of disease onset (day 1), day 2, 3, 5, 7, and 10. Firstly, the diagnostic value of CRP and PCT for the diagnosis of a septic shock, as well as for the discrimination of positive blood cultures, was tested. Secondly, the prognostic value of the CRP and PCT was tested for 30-day all-cause mortality. Statistical analyses included univariable t-tests, Spearman's correlations, C-statistics, and Kaplan-Meier analyses.
A total of 349 patients were included, of which 56% had a sepsis and 44% a septic shock on day 1. The overall rate of all-cause mortality at 30 days was 52%. With an area under the curve (AUC) of 0.861 on day 7 and 0.833 on day 10, the PCT revealed a superior AUC than the CRP (AUC 0.440-0.652) with regard to the discrimination between patients with sepsis and septic shock. In contrast, the prognostic AUCs for 30-day all-cause mortality were poor. Both higher CRP (HR = 0.999; 95% CI 0.998-1.001; p = 0.203) and PCT levels (HR = 0.998; 95% CI 0.993-1.003; p = 0.500) were not associated with the risk of 30-day all-cause mortality. During the first 10 days of ICU treatment, both CRP and PCT declined irrespective of clinical improvement or impairment.
PCT was a reliable diagnostic tool for the diagnosis of septic shock compared to CRP. Both CRP and PCT were shown to have poor predictive value with regard to 30-day all-cause mortality and were not associated with the risk of all-cause mortality in patients admitted with sepsis or septic shock.
本研究旨在探讨 C 反应蛋白(CRP)和降钙素原(PCT)在脓毒症和脓毒性休克患者中的诊断和预后价值。
目前关于 CRP 和 PCT 在脓毒症或脓毒性休克病程中的预后价值的数据有限。
本研究为单中心研究,纳入了 2019 年至 2021 年期间的连续脓毒症和脓毒性休克患者。采集患者发病当天(第 1 天)、第 2、3、5、7 和 10 天的血样。首先,检测 CRP 和 PCT 对脓毒性休克的诊断价值,以及对阳性血培养的鉴别诊断价值。其次,检测 CRP 和 PCT 的预后价值,以评估 30 天全因死亡率。统计分析包括单变量 t 检验、Spearman 相关分析、C 统计量和 Kaplan-Meier 分析。
共纳入 349 例患者,其中 56%在第 1 天患有脓毒症,44%患有脓毒性休克。30 天全因死亡率为 52%。第 7 天和第 10 天 PCT 的 AUC 分别为 0.861 和 0.833,优于 CRP(AUC 0.440-0.652),在鉴别脓毒症和脓毒性休克患者方面具有更好的诊断价值。相比之下,CRP 和 PCT 对 30 天全因死亡率的预后 AUC 较差。CRP(HR=0.999;95%CI 0.998-1.001;p=0.203)和 PCT 水平(HR=0.998;95%CI 0.993-1.003;p=0.500)均与 30 天全因死亡率风险无显著相关性。在 ICU 治疗的前 10 天,无论临床改善还是恶化,CRP 和 PCT 水平均呈下降趋势。
与 CRP 相比,PCT 是诊断脓毒性休克的可靠工具。CRP 和 PCT 对 30 天全因死亡率的预测价值均较差,与脓毒症或脓毒性休克患者的全因死亡率风险无关。